GGTI-298 TFA - CAS# 1217457-86-7 60002 Harmine was dosed orally to

Harmine was dosed orally to obese db/db mice at 30 mg/kg

OTS514 HCl

CUDC-907 was orally dosed to mice at 100 mg/kg or intravenously dosed at 50 mg/kg once per day in the xenograft tumor model of SU-DHL4 (DLBCL) and A549 (NSCLC)

Smiles: O=C1C2=NC3=NON=C3N=C2C2=CC=CC=C21

of apparent translational significance

GGTI-298 TFA - CAS# 1217457-86-7 60002 Harmine was dosed orally toGGTI 298 TFA, CAS No. 1217457 86 7, is a potent geranylgeranyltransferase I (GGTase I) inhibitor with potential antitumor actrivity. GGTI 298 disrupts MAP kinase activation and G(1) S transition in Ki Ras overexpressing transformed adrenocortical cells. GGTI 298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin dependent kinase inhibitors. A potential mechanism for GGTI 298 antitumor activity. GGTI 298 arrests human tumor